Carfilzomib-Associated Cardiovascular Adverse Events

This systematic review with meta-analysis examines the rates of cardiovascular adverse events among patients receiving carfilzomib for the treatment of multiple myeloma.

from Cancer via ola Kala on Inoreader http://ift.tt/2CiBVgE
via IFTTT